On September 13, GlaxoSmithKline (GSK) announced that the FDA’s Vaccines and Related Biological...
- Could a new gene-editing technology permanently cure Duchenne muscular dystrophy?
- GlobalData reports strong growth in monoclonal antibodies during clinical trials from 2007-2016
- GSK’s Shingrix set to disrupt the herpes zoster vaccine marketplace
- Failure of first lampalizumab Phase III study could delay availability
- Lack of sleep increases risk of Alzheimer’s disease
Could a new gene-editing technology permanently cure Duchenne muscular dystrophy?
Scientists at the University of California, Berkeley, have engineered a new way to deliver CRISPR gene-editing technology inside cells, and have demonstrated in mice that it can repair the faulty gene mutation that causes the severe muscle-wasting disease Duchenne muscular dystrophy.
Fiasp (insulin aspart) for the Treatment of Type 1 and Type 2 Diabetes
Discovered and developed by Novo Nordisk, Fiasp® (insulin aspart) is a fast-acting insulin analogue indicated for the treatment of adults with Type 1 and Type 2 diabetes.
GlobalData reports strong growth in monoclonal antibodies during clinical trials from 2007-2016
As part of our series of white papers tracking clinical trials activity across the world, GlobalData recently compiled a summary of global clinical trials in monoclonal antibodies (mAb).
Dynamic Light Scattering – Common Terms Defined
There are a number of sources of information that give a mathematical description of the terms used in light scattering. However, these will not usually give assistance in understanding their practical application.
Benefits of Trehalose
Products such as monoclonal antibodies (mAb), fusion proteins, peptides, vaccines, antibody drug conjugulates (ADC) and stem cells benefit from the stabilising effects of Trehalose.
Application: Operating Reactor Systems for Process Research and Development
In this case study, three reactor systems (FlexyCUBE 70ml, FlexyPAT 2l, and ChemTeacktor 25l) are operated on the same PC using application software FlexySys.
FDA Approves First Cancer Biosimilar – but That Doesn’t Mean It Will Be Available to Patients Anytime Soon
The FDA has approved the first biosimilar to blockbuster cancer therapy Avastin (bevacizumab). But with only three out of the current seven FDA-approved biosimilars available for sale, patients may be waiting a long time for this cost-saving therapy.
Carbohydrates Could be Crucial to an Effective Malaria Vaccine
Despite the need for a vaccine to prevent malaria, particularly in infants and young children, R&D efforts to date have been plagued by a lack of protective efficacy, particularly related to the duration of protection. Even the most advanced vaccine candidate, GlaxoSmithKline’s (GSK’s) subunit vaccine Mosquirix (RTS,S/AS01), possesses clear drawbacks in its ability to effectively protect those who are most vulnerable to severe infections.
GSK’s Shingrix set to disrupt the herpes zoster vaccine marketplace
On September 13, GlaxoSmithKline (GSK) announced that the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the approval of its investigational vaccine, Shingrix (zoster vaccine, recombinant [adjuvanted]), for the prevention of herpes zoster (HZ) in adults ≥50 years of age.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.